We have just released the latest data update to the Open Targets Platform — 22.09.
This release integrates new data from a number of providers including Open Targets Genetics and Genomics England PanelApp, and incorporates new studies in our gene burden widget.
This release integrates 14,229,684 evidence strings to build 7,003,171 target-disease associations between 20,931 diseases and 61,888 targets from the following 22 public resources:
- 1,540,741 genetic evidence from European Variation Archive (EVA)
- 653,757 genetic evidence from Open Targets Genetics
- 3,638 genetic evidence from Gene2Phenotype
- 35,690 genetic evidence from the Genomics England PanelApp
- 1,679 genetic evidence from ClinGen
- 6,047 genetic evidence from Orphanet
- 27,276 genetic evidence from Gene burden
- 5,827 genetic evidence from UniProt Literature
- 12,329 somatic evidence from European Variation Archive (EVA)
- 3,299 somatic evidence from intOGen
- 75,082 somatic evidence from the Cancer Gene Census
- 37,253 somatic evidence from Uniprot
- 601,639 drug evidence from ChEMBL
- 230,971 expression evidence from Expression Atlas
- 10,306 affected pathway evidence from Reactome
- 72,294 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,298 somatic evidence from the Cancer Genome Interpreter
- 1,846 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,136,001 mouse model evidence from IMPC
- 9,771,944 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 12,854 drugs.
For more details, read the 22.09 release blog post.